Magaldrate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Magaldrate
Magaldrate.png
Systematic (IUPAC) name
Magnesium aluminate monohydrate
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a682683
Pregnancy
category
  • C
Routes of
administration
Oral
Legal status
Legal status
  • OTC
Pharmacokinetic data
Bioavailability Negligible
Metabolism Nil
Excretion Fecal and renal
Identifiers
CAS Number 1317-26-6 YesY
ATC code A02AD02 (WHO)
A02AF01 (WHO) (combination with antiflatulents)
PubChem CID 6336542
ChemSpider 4891688 YesY
UNII 6V88E24N5T YesY
Chemical data
Formula AlMg2(OH)7·H2O
Molar mass 212.66 g/mol
  (verify)

Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.

Available forms[edit]

Magaldrate is available in the form of oral suspension or tablets.

Pharmacology[edit]

Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and thus provide a sustained antacid effect.[1]

Interactions and adverse reactions[edit]

Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.

References[edit]

  1. ^ Laurence L., Brunton. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th ed.